Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345265 · ClinicalTrials.gov registry record · Phase 2
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
A Phase 2 study of Ovarian Carcinoma and Primary Peritoneal Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT02345265 is a Phase 2 study of Ovarian Carcinoma and Primary Peritoneal Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants, below the 3,242-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02345265, a Phase 2 study of Ovarian Carcinoma and Primary Peritoneal Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Biopsy Procedure
- PROCEDURE Echocardiography Test
- DRUG Cediranib Maleate
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Los Angeles General Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Keck Medical Center of USC Pasadena - Pasadena
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
- National Institutes of Health Clinical Center - Bethesda
- NCI - Center for Cancer Research - Bethesda
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
Florida
- Mayo Clinic in Florida - Jacksonville
- Moffitt Cancer Center - Tampa
New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital - New Brunswick
- Rutgers Cancer Institute of New Jersey - New Brunswick
Minnesota
- Mayo Clinic in Rochester - Rochester
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2016-05-23 |
| Est. Completion | 2026-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345265
The ClinicalTrials.gov registry entry for NCT02345265 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,242-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (98% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Ovarian Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT02345265 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02345265 about?
NCT02345265 is a clinical study titled "Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer". This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of...
What is the current status of trial NCT02345265?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2016-05-23. Estimated completion is 2026-11-25.
What conditions does trial NCT02345265 study?
This clinical trial studies the following conditions: Ovarian Carcinoma, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma.
What interventions are being tested in trial NCT02345265?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Biopsy Procedure (PROCEDURE), Echocardiography Test (PROCEDURE), Cediranib Maleate (DRUG).
Who is sponsoring clinical trial NCT02345265?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02345265 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
ACTIVE NOT RECRUITING · Phase 2
-
HOT: HIPEC in Ovarian Cancer as Initial Treatment
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.